When was Dali Medical Devices founded?

Dali Medical Devices was founded in 2003.

Where is Dali Medical Devices located?

Dali Medical Devices is headquartered in Rishon Lezion, Israel.

Who is the current CEO of Dali Medical Devices?

David Daily of Dali Medical Devices.

How many employees does Dali Medical Devices have?

As of Jul 01, 2024, the latest employee count at Dali Medical Devices is 17.

Is Dali Medical Devices a funded company?

Dali Medical Devices is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Dali Medical Devices rank among its competitors?

Dali Medical Devices ranks 50th amongst 76 active competitors, of which 27 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was TriSalus Life Sciences, which secured $22M in Apr, 2025.

Who are the top competitors of Dali Medical Devices?

Dali Medical Devices' top competitors include TriSalus Life Sciences, Lyra Therapeutics and Mercator MedSystems. Among them, TriSalus Life Sciences secured the most recent funding round in April, 2025.

Dali Medical Devices - 2026 Company Profile, Team & Competitors

Company Details

Dali Medical Devices focuses on the development of injectable drug delivery technologies from product concept to commercialization. The products of Dali comprises of the SAN (Safe Auto-Needle) product family. The injectors can be customized for use with all types of syringes or primary drug containers: conventional plastic hypodermics, single- or dual-chamber prefilled syringes made of glass or plastic, or vials. The products are- SAN-L (for any type of Luer syringe), SAN-P (for staked needle prefilled syringes, SAN-DV & SAN- DV Pro (for use with drugs in vitals), and SAN- Light (safety needle for any type of Luer syringe).

Key Metrics

Founded Year

2003

Location

Rishon Lezion, Israel

Stage

Unfunded

Ranked

50^th among 76 active competitors

Employee Count

17 as on Jul 01, 2024

Similar Companies

TriSalus Life Sciences & 88 more

View Dali Medical Devices' full profile

Dali Medical Devices has not raised any funding rounds yet.

The founders of Dali Medical Devices are Lior Raday and David Daily.

Here are the details of Dali Medical Devices' key team members:

Lior Raday: Co-Founder And Chief Technology Officer of Dali Medical Devices.
David Daily: CEO & Co-Founder of Dali Medical Devices.
Contact Info: 1 email address

View details of Dali Medical Devices's Founder profiles and Board Members

Dali Medical Devices' employee count trend

Dali Medical Devices has 17 employees as of Jul 24. Here is Dali Medical Devices's employee count trend over the years:

Employee count trend for Dali Medical Devices

Uncover Dali Medical Devices' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Dali Medical Devices include TriSalus Life Sciences, Lyra Therapeutics and Mercator MedSystems. Here is the list of Top 10 competitors of Dali Medical Devices, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	TriSalus Life Sciences 2009, Westminster (United States), Public	Developer of drug delivery devices to treat cancers	$83.4M	Partisan Management Group, High Country Ventures ... & 7 others	68/100
2nd	Lyra Therapeutics 2005, Watertown (United States), Public	Biotechnology firm innovating localized therapies for chronic rhinosinusitis (CRS)	$110M	Perceptive Advisors, HTIF & 9 others	65/100
3rd	Mercator MedSystems 2000, San Leandro (United States), Series D	Developer of catheter-guided microfluid injection systems	$31.8M	Shenzhen Xinlitai Pharmaceutical, Aphelion Capital ... & 5 others	63/100
4th	Halozyme 1999, San Diego (United States), Public	Developer of drug delivery technologies for the treatment of various diseases	-	Colt Ventures, BB Biotech & 8 others	63/100
5th	Genprex 2009, Austin (United States), Public	Developer of therapeutics to treat cancer at molecular level	$3.11M	Inception Capital Management, NIH & 1 others	60/100
6th	Foresee Pharmaceuticals 2011, Taipei (Taiwan), Public	Developer of injectables and NCEs for cancer and chronic diseases	$32.5M	CDIB Capital Group, Vivo Capital & 4 others	58/100
7th	Cellectar Biosciences 2002, Florham Park (United States), Acquired	Developer of phospholipid drug conjugates (PDC) to treat cancer	-	ADAR1 Capital Management & 10 others	57/100
8th	MedinCell 2002, Jacou (France), Public	Developer of a portfolio of long-acting injectables in various therapeutic areas	-	Credit Mutuel Equity, Wellington & 9 others	55/100
9th	RenovoRx 2009, Los Altos (United States), Public	Developer of endovascular catheters for targeted delivery of IV fluids to peripheral organs	$10.9M	Golden Seeds, Boston Scientific & 10 others	54/100
10th	Sixfold Bioscience 2017, London (United Kingdom), Seed	Developer of oligonucleotide delivery systems	$10.5M	Cantos Ventures, Y Combinator & 4 others	52/100
50th	Dali Medical Devices 2003, Rishon Lezion (Israel), Unfunded	Injectable drug delivery devices	-	-	25/100